Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2021
U.S. patent applications covering cytisinicline dosing regimen allowed
Achieve Life Sciences announced that the U.S. Patent and Trademark Office had allowed two patent applications covering a 3.0 mg three-times-daily cytisinicline dosing regimen.
2021
Achieve Life Sciences prices $20 million public offering
Achieve Life Sciences announced pricing for an underwritten public offering of 2,857,143 common shares at $7.00 per share. The offering was expected to close on or about May 27, 2021, subject to customary closing conditions.
2019
Achieve Life Sciences prices a $12 million public offering
Achieve Life Sciences announced the pricing of an underwritten public offering of units expected to generate $12 million in gross proceeds. The offering was expected to close on December 19, 2019, subject to customary closing conditions.
2019
Achieve reports third-quarter 2019 financial results
Achieve Life Sciences announced its third-quarter 2019 financial results, reporting a net loss of $3.7 million for the quarter.